Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.86 EUR
Change Today -0.008 / -0.92%
Volume 0.0
BHN On Other Exchanges
Symbol
Exchange
Toronto
OTC US
Frankfurt
As of 9:37 AM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

bellus health inc (BHN) Snapshot

Open
€0.87
Previous Close
€0.87
Day High
€0.87
Day Low
€0.84
52 Week High
09/3/14 - €1.33
52 Week Low
01/20/15 - €0.61
Market Cap
40.7M
Average Volume 10 Days
74.8
EPS TTM
--
Shares Outstanding
47.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BELLUS HEALTH INC (BHN)

Related News

No related news articles were found.

bellus health inc (BHN) Related Businessweek News

No Related Businessweek News Found

bellus health inc (BHN) Details

BELLUS Health Inc., together with its subsidiaries, focuses on the research and development of pharmaceutical drug candidates. The company’s lead program is KIACTA, which is in Phase III clinical trial for the treatment of AA amyloidosis. It is also developing KIACTA for the treatment of chronic sarcoidosis. The company’s clinical stage drug candidate is Shigamab, a monoclonal antibody therapy for the treatment of hemolytic uremic syndrome caused to Shiga toxin-producing E. coli, as well as has a research project to identify drug candidates for the treatment of AL amyloidosis. It has a strategic partnership with Auven Therapeutics for the development of KIACTA and Pharmascience Inc. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Founded in 1993

bellus health inc (BHN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$319.0K
Vice President of Finance
Total Annual Compensation: C$172.4K
Senior Vice President of Drug Development
Total Annual Compensation: C$325.0K
Vice President of Business Development
Total Annual Compensation: C$176.8K
Compensation as of Fiscal Year 2014.

bellus health inc (BHN) Key Developments

BELLUS Health Inc. Announces Earnings Results for the First Quarter Ended March 31, 2015

BELLUS Health Inc. announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operating activities of CAD 256,000 compared to an income from operating activities of CAD 879,000 for the same quarter ended March 31, 2014. Loss before income taxes was CAD 12,000 compared to a loss before income taxes of CAD 708,000 for the same quarter ended March 31, 2014.

Bellus Health Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015

BELLUS Health Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company’s revenues were CAD 786,000 compared to CAD 475,000 a year ago. Net loss attributable to shareholders was CAD 46,000 or CAD 1 per basic and diluted share, compared to CAD 680,000 or CAD 0.01 per basic and diluted share, a year ago. The increase is primarily attributable to sales-based royalty revenue received in 2015 in relation to the VIVIMIND license agreement with FB Health. The increase is also attributable to higher revenue recognized for accounting purposes in 2015 in relation to the service agreement with Auven Therapeutics for KIACTA.

BELLUS Health Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-04-2015 11:00 AM

BELLUS Health Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-04-2015 11:00 AM. Venue: Sheraton Centre Toronto Hotel (Corner of York and Queen St. West), Toronto, Ontario, M5H 3M9, Canada. Speakers: Roberto Bellini, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BHN:GR €0.86 EUR -0.008

BHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amorfix Life Sciences Ltd C$0.04 CAD -0.01
Eli Lilly & Co $77.83 USD -0.12
Novartis AG SFr.97.00 CHF +0.70
Pfizer Inc $34.41 USD -0.08
View Industry Companies
 

Industry Analysis

BHN

Industry Average

Valuation BHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.2x
Price/Book 7.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BELLUS HEALTH INC, please visit www.bellushealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.